Registration & Networking Breakfast

Welcome and Opening Remarks: Rich Aldrich, Michelle Dipp, Ashley Dombkowski, David Donabedian, Steve Engen, Robert Forrester, Jean George, Steven Holtzman, Neil Kirby, John Maraganore, Brian McVeigh, Mark Miller, Adelene Perkins, Laurence Reid, Jason Rhodes, James Sabry, Rick Shea, Christoph Westphal, Barbara Yanni

Keynote Speaker
Larry Summers, University Professor, Harvard (former President of Harvard, US Treasury Secretary)

Deleterious Me: Whole Genome Sequencing, 23andMe, and the Crowd-Sourced Health Care Revolution
Anne Wojcicki, 23andMe

Mergers & Acquisitions
Drew Fromkin, former CEO, Clinical Data; Nick Galli, Genentech; Rajiv Kaul, Fidelity; Roger Sawhney, Novartis Pharma AG, Larry Wittenberg, Goodwin Proctor
Moderator: Jonathan Gertler, Back Bay Life Science Advisors

Large Biotech
Jim Frates, Alkermes; Steve Holtzman, Biogen; Tony Rosenberg, Novartis; Praveen Tipirneni, Cubist
Moderator: Mark Miller, Eli Lilly

Payors and Providers
Charlie Baker, General Catalyst; Kevin Tabb, Beth Israel Deaconess Medical Center
Moderator: Greg Pachus, Silicon Valley Bank

Small Biotech
Kees Been, EnVivo Pharma; Luc Dochez, Prosensa; Dan Paterson, Verastem; Duncan Higgons, Agios Pharmaceuticals; Jigar Raythatha, Constellation Pharmaceuticals
Moderator: Art Cook, ZS Associates

Networking Break

The West Coast Perspective
Juergen Lasowski, Onyx Pharmaceuticals; Jonathan Lim, City Hill Ventures; John Mendlein, aTyr Pharma
Moderator: Ashley Dombkowski, 23andme

Mid-size Biotech
Josh Hammermesh, Infinity; Julie McHugh, Endo Pharmaceuticals; Stu Randle, GI Dynamics; Laurence Reid, Alnylam; Rick Shea, Momenta
Moderator: Michelle Dipp, OvaScience

R&D
Richard Eglen, Corning; Brian McVeigh, GlaxoSmithKline; Roger Pomerantz, Merck
Moderator: Rich Aldrich, Longwood Fund

Rare Diseases
Bob Coughlin, Massachusetts Bio Council; Cyrus Mozayeni, Bluebird Bio; Deanna Petersen, Shire; Dan Regan, Inspiration Biopharmaceuticals
Moderator: Neil Kirby, Edimer Pharmaceuticals

Networking Lunch

Buyside
Howard Furst, Deerfield Partners; Andrew Hatem, Fidelity Management & Research; Adam Koppel, Brookside Capital
Moderator: Mike King, Rodman & Renshaw

Accessing Biotech and Academia
Jessie English, The Belfer Institute for Applied Cancer Science; David Sinclair, Department of Genetics, Harvard Medical School; Frank Stonebanks, Triphase
Moderator: Jon Pachter, Verastem

European and Asian Perspectives
Christoph Boehringer, Mediatum and CD-Venture; Larry Cai, Medicilon; Philipp von Gallwitz, Grünenthal Group; John Oyler, BeiGene; David Phillips, SR One
Moderator: Rüdiger Herrmann, WilmerHale

Networking Break

Venture Capital
Bruce Booth, Atlas Venture; Jens Eckstein, SR One; Brian Halak, Domain Associates; Reid Leonard, Merck; Alan Walts, Genzyme Ventures
Moderator: Garheng Kong, Sofinnova Ventures

New Directions in Pharma BD
Darren Carroll, Eli Lilly; Brian McVeigh, GlaxoSmithKline; Christopher Seaton, Bayer; Barbara Yanni, Merck
Moderator: Jeremy Goldberg, Torreya Partners

Patient Perspectives
Mary Lynne Hedley, TESARO; Jason Rhodes, Epizyme; Carlo Russo, GlaxoSmithKline; Sameer Sabir, MoMelan Technologies
Moderator: Eileen Coveney, L.E.K. Consulting

Changing Reimbursement Landscape
Mark Enyedy, Proteostasis Therapeutics; Jim Frates, Alkermes; Eric Grinstead, Synageva
Moderator: Peter Thompson, OrbiMed Advisors

Structuring Deals: The Future
Rich Aldrich, Longwood Fund; Steve Bernitz, Extera Partners; David Donabedian, Locust Walk; Imran Eba, GlaxoSmithKline; James Geraghty, Genzyme
Moderator: David Redlick, WilmerHale

Lifetime Achievement Award & Cocktails and hors d'oeuvres
Nominees: Rich Aldrich, Duncan Higgons, David Schenkein

Registration & Networking Breakfast

NY Biotech Initiative
Ron Cohen, Acorda Therapeutics; Mikael Dolsten, Pfizer; Greg Plowman, Eli Lilly; Marc Tessier-Lavigne, Rockefeller University
Moderator: Jean-Francois Formela, Atlas Ventures

Partnership Between FDA & Drug Development
Vicki Seyfert-Margolis, Office of the Commissioner, FDA

Biotechnology Industry Organization (BIO) Initiatives
Josh Boger, Founder Vertex; Jim Greenwood, BIO

Networking

Two Concurrent Workshops (see full agendas below)

Orphan Drug Summit (Oriental Ballroom)

Fertility Summit (Bangkok Room)

Wine and cheese

Orphan Drug Development and Regulation: Abbie Celniker, Eleven Biotherapeutics; Nick Leschly, Bluebird Bio; Arthur Tzianabos, Shire; Tim Cote, NORD
Moderator: Neil Kirby, Edimer Pharmaceuticals

Orphan Drug Company Strategies: JC Gutierrez-Ramos, Pfizer; Claudia Hirawat, PTC Therapeutics
Moderator: Mike Gilman, Stromedix

Business Development and Role of VC in Orphan Drug Development: Ashley Dombkowski, 23andMe; Alan Walts, Genzyme Ventures; Christoph Westphal, Verastem
Moderator: John Ripple, Ripple Biotech

Patient Associations: Tim Cote, NORD

Commercial Strategies: Chris Adams, Formerly FoldRx/Pfizer; Tony Rosenberg, Novartis; Barry Frankel, Frankel Group
Moderator: Barbara Deptula, Shire

10:00 - 10:25 am Bioenergetics in IVF: David Sable, Special Situations Life Sciences Fund
10:25 - 10:45 am The Role of Mitochondria in Fertility: Robert Casper, University of Toronto
Moderator: Christopher Bleck, OvaScience

New Advances in Fertility Treatment: Benjamin Leader, ReproSource, Inc.; Alan Penzias, Harvard Medical School, BIDMC, Boston IVF; Mitchell Rosen, University of California, San Francisco
Moderator: Thomas Toth, Mass General Hospital & Harvard Medical School

Fertility and Aging: Jonathan Tilly, MGH & Harvard Medical School; David Sinclair, Harvard Medical School
Moderator: Scott Chappel, OvaScience

Patient Advocacy: Barbara Collura, RESOLVE: The National Infertility Association; Erin Lasker, RESOLVE New England
Moderator: Michelle Dipp, OvaScience